Researchers at The Wistar Institute and the University of South Florida have advanced a novel compound that specifically targets the endoplasmic reticulum (ER) stress response that is frequently hyperactivated in cancer and promotes survival of cancer cells during stressful conditions. The new compound has unique chemical properties that allow for precise activation and can be used for tracking its activity in vivo thanks to the emission of fluorescence.
Research was published online in the Journal of Medicinal Chemistry.
The ER is a cellular structure that oversees protein folding and assembly, and it activates stress response mechanisms in response to the accumulation of misfolded proteins or other stressful conditions, including low oxygen.
“Certain cancers rely on the protective role of the ER stress response to sustain their growth in stressful environmental conditions,” said Chih-Chi Andrew Hu, Ph.D., associate professor in Wistar’s Immunology, Microenvironment & Metastasis Program, and co-lead author on the study with Juan R. Del Valle, Ph.D., from the University of South Florida. “We and other groups showed that genetically and pharmacologically targeting the ER is a very effective way to attack various tumors.”
The Hu lab has been actively advancing a research program for development of compounds to block vital functions of the ER stress response, specifically inhibitors of the IRE1 protein that senses the ER stress and responds by activating a cascade of cellular events. In addition to inducing tumor cell apoptosis, these compounds activate antitumor T-cell function and inhibit tumor-associated immunosuppressive cells in vivo in mouse models, resulting in tumor shrinkage.
“This class of inhibitors has shown therapeutic promise in several cancer types, including chronic lymphocytic leukemia and Burkitt lymphoma,” said Hu. “Therefore, we are very interested in advancing them to the clinic.”
In this study, through a series of chemical modifications, Hu and collaborators created a molecule called PC-D-F07 that is pharmacologically inactive and requires UV irradiation to be “turned on” and converted into the active D-F07, which is a very potent inhibitor of IRE-1 function.
The novel prodrug strategy enhances the efficacy of IRE-1 inhibitors and allows fine control of their activity at a precise time and location by UV irradiation. Importantly, once active, D-F07 emits fluorescence that can be tracked in cells and potentially in vivo, providing a real-time therapy readout. This new strategy for stimulus-mediated release of pharmacological activity provides a promising platform to target the ER stress response for anticancer therapy and for developing other potent inhibitors.
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Mystery about the cancer drug nelarabine solved after decadeson June 24, 2020 at 9:12 am
Acute lymphoblastic leukemia (ALL) is the most common kind of cancer in children. T-ALL, a subtype that resembles T-lymphocytes, can be treated successfully with the drug nelarabine. The drug has not ...
- Glottic Cancer Treatment Market – What Are The Main Factors That Contributing Towards Industry Growth? | Impact of COVID-19 Pandemicon June 24, 2020 at 9:01 am
Kenneth Research has published a detailed report on Glottic Cancer Treatment Market which has been categorized by ...
- Research uncovers clues in use of immunotherapy for breast canceron June 24, 2020 at 9:01 am
UC researchers have found a potential new combination therapy for breast cancer that would integrate use of the body's immune system with targeted treatment for a particular protein that advances ...
- Towards Improved Cancer Treatment: IAEA and Okayama University to Cooperate in Boron Neutron Capture Therapy R&Don June 24, 2020 at 8:28 am
Image of new boron compounds uptake into glioblastoma cancer cells (green: new boron compounds; red: actin; blue: nucleus). (Photo: Okayama University) Boron Neutron Capture Therapy (BNCT) is a ...
- How One Center Continues Cancer Clinical Trials Despite COVID-19on June 24, 2020 at 7:15 am
Whereas many cancer trials around the world have been suspended, the University of Iowa's Holden Comprehensive Cancer Center is still offering 95% of its program despite COVID-19.
- More Than 10,000 Excess Cancer Deaths due to COVID-19 Delayson June 24, 2020 at 6:41 am
The National Cancer Institute predicts that more than 10,000 excess cancer deaths will occur during next 10 years because of delays in diagnosis and treatment as a result of the COVID-19 pandemic.
- Carlisle boy Stanley Dalton in cancer treatment race against timeon June 24, 2020 at 4:14 am
His family were told earlier this month his cancer had returned after he was twice in remission. "It was a total shock," Ms Brecken said. "We were told his leukaemia was back and that they couldn't ...
- Pause in cancer treatments during COVID may cause other public health crisison June 24, 2020 at 2:25 am
"Less cancer is being diagnosed but we think the incidence of cancer during this period is the same," he said in an interview with ABC News. "These cancers will eventually come to ...
- Cancer drug tocilizumab may help curb severe COVID-19on June 24, 2020 at 12:36 am
Could a cancer drug spare hospital patients from the ravages of severe COVID-19? Yale doctors think it can after giving the medication, known as tocilizumab, to severely ill patients back in March.
- Radiotherapy targeting cancer stem cells “awakens” them to induce tumour relapse and metastasis in oral canceron June 23, 2020 at 3:16 pm
Radiotherapy is one of the most common treatments for oral cancer. However, in the clinic, recurrence and metastasis of oral cancer occur after radiotherapy, and the underlying mechanism remains ...
via Bing News